Review decision: May 2012
Review of NICE Technology Appraisal Guidance 101: Docetaxel for the treatment of hormone refractory prostate cancer
The Institute was proposing the guidance should be transferred to the ‘static guidance list’ and that the existing recommendations within TA101 be incorporated into the on-going update of clinical guideline CG58 ‘Prostate cancer: diagnosis and management’.
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal. The guidance will now be transferred to the list of static appraisals and incorporated into the ongoing update of clinical guideline CG58.
This page was last updated: 22 May 2012